Journal of Sasang Constitutional Medicine (사상체질의학회지)

The Society Of Sasang Constitutional Medicine (사상체질의학회)
권호 표지
DOI QR코드

DOI QR Code

Impact of the Sasang Constitutional Type on the High-Sensitivity C-Reactive Protein, a Predictor of Cardiovascular Disease

사상체질(四象體質)과 심혈관질환 예측인자인 High-sensitivity C-reactive protein의 상관성에 관한 연구

  • 강미정 (경희대학교 대학원 임상한의학과 체질의학전공) ;
  • 이지원 (경희대학교 한의과대학 사상체질과) ;
  • 이의주 (경희대학교 한의과대학 사상체질과) ;
  • 고병희 (경희대학교 한의과대학 사상체질과) ;
  • 이준희 (경희대학교 한의과대학 사상체질과)
  • Received : 2011.10.29
  • Accepted : 2011.12.02
  • Published : 2011.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

1. Objectives The purpose of this study was to investigate the high-sensitivity C-reactive protein (hsCRP) related characteristics found in each Sasang Constitutional type. 2. Methods This cross-sectional epidemiological study was conducted using data from 2,842 men and women. After typing each participant into one of the four Sasang constitutional types, they were analyzed on various cardiovascular disease-related variables. 3. Results 1) The predictors of cardiovascular disease (metabolic syndrome, high risk FRS group, high risk hsCRP group) was found to show the highest prevalence in the Taeeum type. 2) In the group with metabolic syndrome, the mean hsCRP concentration in the Taeeum and Soyang types were higher than in the Soeum type. In the group without metabolic syndrome, the mean hsCRP concentration in the Taeeum type were higher than in the Soyang and Soeum types. 3) In the FRS low risk group, the mean hsCRP concentration were higher in order of Taeeum type > Soyang type > Soeum type. In the FRS high risk group, the mean hsCRP concentrations were not significantly different among the Sasang constitutional types. 4. Conclusions The results of this study suggest that the Taeeum constitutional type is a risk factor for high hsCRP and cardiovascular disease. These findings suggest that the prevention of cardiovascular disease is more important in the Taeeum type compared to other constitutional types. Moreover, preventive measures are warranted even in the Taeeum-type persons with low clinical cardiovascular risk.

Keywords

References

  1. Available from:URL:http://kostat.go.kr/portal/korea/index. action.
  2. Wannamethee SG, Shaper G, Lennon L, Morris RW. Metabolic Syndrome vs Framingham Risk Score for Prediction of Coronary Heart Disease, Stroke, and Type 2 Diabetes Mellitus. Arch Intern Med. 2005;165: 2644-2650. https://doi.org/10.1001/archinte.165.22.2644
  3. Casas JP, Shah T, Higorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008;264(4):295-314. https://doi.org/10.1111/j.1365-2796.2008.02015.x
  4. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; National Heart, Lung, and Blood Institute; American Heart Association. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004;24(2):13-18. https://doi.org/10.1161/01.ATV.0000111245.75752.C6
  5. Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Fleming C, et al. LL. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):496-507. https://doi.org/10.7326/0003-4819-151-7-200910060-00010
  6. Roberts WL, Sedrick R, Moulton TKL, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem. 2000;46(4): 461-8.
  7. Chol JY, Park SS. A clinical study for 157 cases of CVA by Sasang Constitutional Medicine. J Sasang Constitut Med. 1998;10(2):431-453.
  8. Yang SM, Yoo JS, Koh SB, Park JK. Association between risk factors and prevalence of Metabolic Syndrome according to Sasang Constitution in Wonju cohort study. J Sasang Constitut Med. 2009;21(1):186-196. (Korean).
  9. Ham TI. The prevalence and risk factors of the Metabolic Syndrome according to Sasang Constitution in middle aged persons. Dept of Oriental Medicine, Graduate school, Kyunghee University, Seoul, Korea.(Korean).
  10. Lee TG. Koh BH. Lee, SK. Sasang constitution as a risk factor for diabetes mellitus: a cross-sectional study. Evid Based Complement Alternat Med. 2009;6(1):99-103. https://doi.org/10.1093/ecam/nem063
  11. Jang HS. The study on Odds Ratio of Dyslipidemia in Different Constitutional Types. Dept of Oriental Medicine, Graduate school, Kyunghee University, Seoul, Korea.(Korean).
  12. Lee TG, Lee SK, Choe BK, Song IB. A study on the prevalence of chronic diseases according to Sasang Constitution at a health examination center. J Sasang Constitut Med. 2005;17(2):32-45.(Korean).
  13. Choi KJ, Lee Jh, Yoo JH, Lee EJ, Koh BH. Sasang constitutional types can act as a risk factor for insulin resistance. Diabetes Res Clin Pract. 2011;91(3):57-60. https://doi.org/10.1016/j.diabres.2010.11.017
  14. Han KS, Bae NY, Lee HE, Ahn TW. A study of relationship between blood chemical risk factor of cardiovascular disease and Sasang Constitution and effect of Oxygen Free Radical on the relationship. J Sasang Constitut Med. 2007;19(2):143-154.(Korean)
  15. Han Ks, Lee HE, Lee JY, Ahn TW. A study of relationship between coronary heart disease risk and Sasang Constitution based on NCEP-ATPIII. J Sasang Constitut Med. 2008;20(3):94-106.
  16. Shim GH, YOo JS, Koh SB, Park JK. A study on the relationship between Sasang Constitution and Framingham Coronary Risk Score. J Sasang Constitut Med. 2009;21(1):165-185.(Korean).
  17. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the Am Heart Association. Circulation. 2003;107:499-511. https://doi.org/10.1161/01.CIR.0000052939.59093.45
  18. Lee SW. Jang ES. Lee J, Kim JY. Current researches on the methods of diagnosing sasang constitution: an overview. Evid Based Complement Alternat Med. 2009;6 Suppl 1:43-9. https://doi.org/10.1093/ecam/nep092
  19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Excutive summary of the third report of the National Cholesterol Education Program(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel Ⅲ). JAMA. 2001;285:2486-2497. https://doi.org/10.1001/jama.285.19.2486
  20. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cut off points for central obesity in Korean adults. Diabetes Res Clin Pract. 2007;75(1):72-80. https://doi.org/10.1016/j.diabres.2006.04.013
  21. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant D, for the Conference Participants. Definition of metabolic syndrome: report of the National, Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438. https://doi.org/10.1161/01.CIR.0000111245.75752.C6
  22. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation. 1982;97(18):1837-47.
  23. Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V, et al. C-Reactive Protein as a Screening Test for Cardiovascular Risk in a Multiethnic Population. Arterioscler Thromb Vasc Biol. 2004;24:1509-1515. https://doi.org/10.1161/01.ATV.0000135845.95890.4e
  24. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. https://doi.org/10.1056/NEJMoa0807646
  25. Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2009;2(1):41-8. https://doi.org/10.1161/CIRCOUTCOMES.108.832592
  26. Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, Matthews KA, Johnston J, Sowers MR, et al. Ethnic differences in C-reactive protein concentrations. Clin Chem. 2008;54(6):1027-37. https://doi.org/10.1373/clinchem.2007.098996
  27. Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, et al. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol. 2008;28(7):1385-91. https://doi.org/10.1161/ATVBAHA.107.157164
  28. Kim HJ, Pae SW, Kim DJ, Kim SK, Kim SH, Rhee YM, et al. Association of serum high sensitivity C-reactive protein with risk factors of cardiovascular disease in type 2 diabetic and nondiabetic subjects without cardiovascular diseases. The Korean Journal of Medicine. 2002;63(1):35-45.(Korean)
  29. Dep. of Sasang Constitutional Medicine of Kyung Hee University. The manual of Dep. of Sasang Constitutional Medicine (subtitle: reference book of Sasang Constitutional Medicine). Seoul:Hanmibook. 2010.(Korean),
  30. Yeo HR, Kim KK, Lee MH, Park Yc, Jeon SH, Kwon SD, et al. A study on the Sasang Constitutional characterisitcs by Obesity Grade. J Sasang Constitu Med. 2008;20(1):89-99.(Korean).
  31. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: 1557-1565. https://doi.org/10.1056/NEJMoa021993
  32. van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med. 2003;163(11): 1323-8. https://doi.org/10.1001/archinte.163.11.1323
  33. Seok JH, Km U, Lee SH, Hong GR, Park JS, Shin DG et al. Correlations of C-reactive protein levels and Frammingham coronary risk score. The Korean Journal of Medicine. 2007;73(3):36-45.(Korean).
  34. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113-32. https://doi.org/10.1016/j.jacc.2010.05.034
  35. Hwang YC, Jee JH, Oh EY, Choi YH, Lee MS, Kim KW, Lee MK. Metabolic syndrome as a predictor of cardiovascular diseases and type 2 diabetes in Koreans. Int J of Cardiology. 2009;134:313-321. https://doi.org/10.1016/j.ijcard.2008.12.025
  36. Bosomworth NJ. Practical use of the Framingham risk score in primary prevention: Canadian perspective. Can Fam Physician. 2011;57(4):417-23.
  37. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116(Suppl 6A):9-16. https://doi.org/10.1016/j.amjmed.2004.02.006
  38. Buckley DI, Fu R, Freeman M, Rogers K, Hefand M. C-reactive protein as a risk factor for coronary heart disease: A systematic review and Meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):483-495. https://doi.org/10.7326/0003-4819-151-7-200910060-00009
  39. Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ.Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ.Eur Heart J. 2010;31(17): 2087-91. https://doi.org/10.1093/eurheartj/ehq238
  40. Anand SS, Yusuf S. C-reactive protein is a bystander of cardiovascular disease. Eur Heart J. 2010;31(17): 2092-6. https://doi.org/10.1093/eurheartj/ehq242